Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
Add more filters










Publication year range
1.
Biol Pharm Bull ; 46(9): 1304-1309, 2023 Sep 01.
Article in English | MEDLINE | ID: mdl-37407483

ABSTRACT

The chronic myelogenous leukemia cell line, K562/ADM is derived from the K562 cell line, which is resistant to doxorubicin (alias, adriamycin: ADM). P-glycoprotein levels are significantly higher in K562/ADM cells than in K562 cells. The overexpression of p-glycoprotein has been shown to cause drug resistance. Therefore, the present study investigated a novel mechanism underlying the drug resistance of K562/ADM cells. A gene ontology analysis demonstrated that the expression of solute carrier (SLC)-mediated transmembrane transport genes was significantly higher in K562/ADM cells than in K562 cells. The expression level of a member of the SLC family, SLC25A40 was higher in K562/ADM cells than in K562 cells. SLC25A40 is located near the ABCB1 gene. A real-time PCR analysis showed that the expression of SLC25A40, ABCB4, and ADAM22 was up-regulated. These genes are located close to SLC25A40. The down-regulation of SLC25A40 significantly decreased the mitochondrial concentration of glutathione and cell proliferation. Collectively, the present results demonstrated that the expression of SLC25A40 was up-regulated in K562/ADM cells, which enhanced to cell proliferation, and that the expression of SLC25A40 affected drug resistance to ADM.


Subject(s)
Antineoplastic Agents , Leukemia, Myeloid , Humans , Antineoplastic Agents/pharmacology , ATP Binding Cassette Transporter, Subfamily B/genetics , ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism , Doxorubicin/pharmacology , Drug Resistance , Drug Resistance, Neoplasm , K562 Cells
2.
Biol Pharm Bull ; 42(11): 1805-1813, 2019 Nov 01.
Article in English | MEDLINE | ID: mdl-31434819

ABSTRACT

Tyrosine kinase inhibitors (TKIs) are used as the first choice for chronic myeloid leukemia (CML) pharmacotherapeutics. Some patients taking these drugs showed good therapeutic reactivity despite the disappearance of drugs from blood. We investigated whether these drugs have sustained effects even after their disappearance and whether their effects depend on their amounts of intracellular accumulation. Cell proliferation after exposure of K562 cells or Multidrug resistance-1 (MDR-1)-transfected K562 cells was determined by a cell counting kit-8 assay. The intracellular accumulation amount of the drug showing a sustained cytostatic effect was measured by ultra high performance liquid chromatography mass spectrometry. Cell viability decreased in a culture time-dependent manner after washing out nilotinib and dasatinib. The sustained cytostatic effect of dasatinib, but not that of nilotinib, correlated with the intracellular accumulation level. In contrast, imatinib showed continuous a cytostatic effect after drug washout for long-term exposure but not after drug washout for short-term exposure. These results suggest that a good response in patients with a low serum concentration of imatinib, nilotinib or dasatinib may be due to the cytostatic effect of that drug continues even after its disappearance in plasma.


Subject(s)
Fusion Proteins, bcr-abl/antagonists & inhibitors , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Protein Kinase Inhibitors/pharmacology , ATP Binding Cassette Transporter, Subfamily B, Member 1 , Antineoplastic Agents/pharmacology , Cell Line, Tumor , Dasatinib/pharmacology , Drug Resistance, Neoplasm/drug effects , Humans , Imatinib Mesylate/pharmacology , K562 Cells , Pyrimidines/pharmacology
3.
Biol Pharm Bull ; 42(8): 1332-1336, 2019.
Article in English | MEDLINE | ID: mdl-31366868

ABSTRACT

MicroRNAs (miRs) are small, non-coding RNAs that negatively regulate gene expression. The stem-loop sequence miR-101-1 generates mature miR-101-5p and miR-101-3p. The function and target mRNA of miR-101-5p have not yet been elucidated in detail. Here, we demonstrate that miR-101-5p inhibits the expression of RAP1A, a member of the RAS gene family. Transfection of a miR-101-5p mimic significantly inhibited the expression of RAP1A mRNA in HeLa, HEK293, A549, and COLO201 cells. The same treatment significantly inhibited cell proliferation. The cytostatic effect with transfection of miR-101-5p was antagonized by treatment with the RAP inhibitor salirasib. These results suggested that miR-101-5p inhibits RAP1A, and thus, the expression levels of miR-101-5p regulate cell proliferation.


Subject(s)
Cell Proliferation/genetics , MicroRNAs/genetics , rap1 GTP-Binding Proteins/genetics , Cell Line, Tumor , HEK293 Cells , Humans , RNA, Messenger/genetics , RNA, Small Interfering/genetics , Signal Transduction , rap1 GTP-Binding Proteins/metabolism
4.
Biol Pharm Bull ; 38(4): 582-6, 2015.
Article in English | MEDLINE | ID: mdl-25739790

ABSTRACT

Regorafenib is a small molecule inhibitor of tyrosine kinases, and has been shown to improve the outcomes of patients with advanced colorectal cancer and advanced gastrointestinal stromal tumors. The transport profiles of regorafenib by various transporters were evaluated. HEK293/organic anion transporting polypeptide 1B1 (OATP1B1) cells exhibited increased drug sensitivity to regorafenib. Regorafenib inhibited the uptake of 3H-estrone sulfate by HEK293/OATP1B1 cells in a dose-dependent manner, but did not affect its elimination by P-glycoproteins. The concentration of regorafenib was significantly lower in LLC-PK1/multidrug resistance protein 2 (MRP2) cells than in LLC-PK1 cells treated with the MRP2 inhibitor, MK571. MK571 abolished the inhibitory effects of regorafenib on intracellular accumulation in LLC-PK1/MRP2 cells. The uptake of regorafenib was significantly higher in HEK293/OATP1B1 cells than in OATP1B1-mock cells. Transport kinetics values were estimated to be Km=15.9 µM and Vmax=1.24 nmol/mg/min. No significant difference was observed in regorafenib concentrations between HEK293/OATP1B3 and OATP1B3-mock cells. These results indicated that regorafenib is a substrate for MRP2 and OATP1B1, and also suggest that the substrate preference of regorafenib may implicate the pharmacokinetic profiles of regorafenib.


Subject(s)
Multidrug Resistance-Associated Proteins/metabolism , Organic Anion Transporters/metabolism , Phenylurea Compounds/pharmacology , Pyridines/pharmacology , Animals , Biological Transport , Cell Line, Tumor , HEK293 Cells , Humans , LLC-PK1 Cells , Liver-Specific Organic Anion Transporter 1 , Multidrug Resistance-Associated Protein 2 , Multidrug Resistance-Associated Proteins/antagonists & inhibitors , Propionates/pharmacology , Quinolines/pharmacology , Swine
5.
Oncol Rep ; 33(5): 2176-82, 2015 May.
Article in English | MEDLINE | ID: mdl-25759982

ABSTRACT

MicroRNAs (miRs) have been shown to negatively regulate gene expression by binding to mRNAs, and they play an important role in various physiological processes and malignancies. A previous study identified mature miR-126-3p as an onco-microRNA that is generated from the pre­microRNA, miR-126. Although miR-126 also generates mature miR-126-5p, its function is less clear. In the present study, the relationship between miR-126-5p/3p expression levels and overall survival in 109 patients with acute myeloid leukemia (AML) who received intensive therapy were evaluated. Higher expression levels above the median value of miR-126-5p/3p were correlated with a poorer overall survival. The hazard ratio and 95% confidence intervals (95% CI) for the higher expression group relative to the lower expression group of miR-126-5p/3p were 2.098 (95% CI: 1.075-4.228) and 1.958 (95% CI: 1.001-3.927), respectively. An interaction was not observed between the hazard ratios of miR-126-5p and miR­126-3p (p=0.73). Transfection of the mimic miR-126-5p into the AML cell line, KG-1, resulted in a decrease in the sensitivity to cytarabin and the expression level of Klotho mRNA as well as the elevation in the phosphorylation of Akt. The results of the present study demonstrated that higher expression levels of miR-126-5p/3p in patients with AML resulted in a poorer prognosis. Furthermore, miR-126-5p elevated the phosphorylation of Akt.


Subject(s)
Antimetabolites, Antineoplastic/therapeutic use , Cytarabine/therapeutic use , Drug Resistance, Neoplasm/genetics , Leukemia, Myeloid, Acute/genetics , MicroRNAs/biosynthesis , Adult , Aged , Blotting, Western , Female , Humans , Kaplan-Meier Estimate , Leukemia, Myeloid, Acute/drug therapy , Leukemia, Myeloid, Acute/mortality , Male , Middle Aged , Prognosis , Real-Time Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction , Up-Regulation , Young Adult
6.
Cancer Med ; 3(6): 1544-52, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25081869

ABSTRACT

A component of polycomb repressor complex 2, enhancer of zeste homolog 2 (EZH2), plays an important role in tumor malignancy and metastasis, while milk fat globule-epidermal growth factor-factor 8 (MFGE8) plays a key role in tumor progression and prognosis. MicroRNAs (miRs) are also critically involved in various physiological and pathological processes. We here evaluated the relationship between overall survival (OS) in colorectal cancer patients and the expression of onco-miRs and miRs, which may target EZH2 and MFGE8. Plasma and formalin-fixed paraffin-embedded (FFPE) samples were obtained from 71 colorectal cancer patients. The expression levels of miRs complementary to EZH2 and MFGE8 mRNA and cancer malignancies were evaluated. The miRs analyzed were as follows: miR-16, miR-21, miR-26a, miR-34a, miR-98, miR-101-3p, miR-101-5p, miR-124-5p (also known as miR-124*), miR-126-3p, miR-126-5p, miR-210, miR-217, and miR-630. The plasma expression levels of MFGE8 in completely resected patients were significantly lower than those in unresectable patients. Lower miR-26a expression levels were correlated with a higher probability of OS. Higher miR-124-5p expression levels in plasma and FFPE samples were correlated with a higher probability of OS. The transfection of mimic miR-124-5p into WiDr and COLO201 cells inhibited the expression of structural maintenance of chromosomes 4 (SMC4) mRNA. Our results indicate that miR-124-5p may target the tumorigenesis gene, SMC4, which suggests that expression levels of miR-124-5p in plasma and FFPE samples; therefore, the expression of MFGE8, miR-26a, and miR-124-5p in plasma may be used as biomarkers to determine the prognosis of colorectal cancer patients.


Subject(s)
Adenosine Triphosphatases/metabolism , Chromosomal Proteins, Non-Histone/metabolism , Colorectal Neoplasms/genetics , MicroRNAs/biosynthesis , Adenosine Triphosphatases/genetics , Adult , Aged , Aged, 80 and over , Antigens, Surface/biosynthesis , Antigens, Surface/blood , Antigens, Surface/genetics , Biomarkers, Tumor/biosynthesis , Biomarkers, Tumor/blood , Biomarkers, Tumor/genetics , Chromosomal Proteins, Non-Histone/genetics , Colorectal Neoplasms/blood , Colorectal Neoplasms/metabolism , Enhancer of Zeste Homolog 2 Protein , Female , Humans , Male , MicroRNAs/blood , MicroRNAs/genetics , Middle Aged , Milk Proteins/biosynthesis , Milk Proteins/blood , Milk Proteins/genetics , Paraffin Embedding , Polycomb Repressive Complex 2/genetics , Prognosis , RNA, Messenger/genetics , RNA, Messenger/metabolism , Transfection
7.
Yakugaku Zasshi ; 132(12): 1329-32, 2012.
Article in Japanese | MEDLINE | ID: mdl-23208036

ABSTRACT

In our unprecedented ageing society, high quality pharmacy practices are recommended; the activities of pharmacists who have received novel education are therefore expected. Although advanced education before graduation is important, postgraduate education is also required because the knowledge and skill required by pharmacists are increasing and are progressing everyday. The period of pharmacist education has been six years, and the new educational system produces next generation pharmacists. Postgraduate education should be established with the education contents corresponding to the new education system. The career path has an important role in postgraduate education, which consists of fundamental to advanced training through the various stages according to pharmacist experience. Clinical academic societies and some pharmacists' organizations provide accreditation systems for pharmacist specialties. This system will play an important role as a route in the career path. It is necessary to accredit pharmacist specialties to establish postgraduate education and research in cooperation with pharmaceutical institutions. It is thought that the responsibility of universities of pharmaceutical science will become more important to improve pharmacist ability and pharmacy practice. Universities of pharmaceutical science should collaborate with pharmaceutical institutions to establish postgraduate education and research into clinical pharmacy practice.


Subject(s)
Education, Pharmacy, Graduate/trends , Specialization/trends , Accreditation/trends , Education, Pharmacy/trends , Education, Pharmacy, Continuing/trends , Humans , Interdisciplinary Communication , Japan
8.
Biol Pharm Bull ; 34(9): 1418-25, 2011.
Article in English | MEDLINE | ID: mdl-21881227

ABSTRACT

5-Fluorouracil (5-FU)-based chemotherapies with irinotecan have been applied for the treatment of cancers, and a common dose-limiting toxicity is neutropenia and diarrhea. In this study, we investigated the effect of 5-FU treatment on expression levels of drug transporters for SN-38 transportation and SN-38 absorption from the intestine following 5-FU treatment. Expression levels of several drug transporters and nuclear receptors in rats after 5-FU treatment were evaluated. SN-38 absorption from the intestine was evaluated by SN-38 concentration levels in serum following SN-38 injection into the intestine of 5-FU treated rats. The levels of renal multidrug resistance protein 2 (Mrp2) on day 4 after treatment (400 mg/kg) showed significant upregulation, 359.2 ± 33.2% (mean ± S.E.) of control. Mrp2 levels in the intestine were downregulated to 26.2 ± 8.4% of control. 5-FU treatment (400 mg/kg) also significantly downregurated expression levels of P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp) to 41.2 ± 14.7%, 15.7 ± 4.3% of control, respectively. To evaluate SN-38 absorption from the intestine, SN-38 was loaded in to the intestine on day 4 after 5-FU treatment. Pretreatment with 5-FU significantly increased SN-38 concentration in the blood 30, 60 and 90 min after SN-38 administration. The area under the curve for SN-38 in the 5-FU group was significantly higher than in vehicle groups. 5-FU treatment decreased expression levels of P-glycoprotein and Bcrp in intestine. The present study suggests that combination chemotherapy of 5-FU with irinotecan (CPT-11) may elevate SN-38 absorption from intestine.


Subject(s)
Camptothecin/analogs & derivatives , Fluorouracil/pharmacology , Intestinal Absorption/drug effects , ATP-Binding Cassette Transporters/genetics , Animals , Base Sequence , Body Weight/drug effects , Camptothecin/pharmacokinetics , Cell Line , DNA Primers , Humans , Irinotecan , Male , Phosphorylation , Polymerase Chain Reaction , Proto-Oncogene Proteins c-jun/metabolism , RNA, Messenger/genetics , Rats , Rats, Wistar , Receptors, Cytoplasmic and Nuclear/genetics
9.
Biol Pharm Bull ; 34(3): 433-5, 2011.
Article in English | MEDLINE | ID: mdl-21372398

ABSTRACT

Sorafenib and sunitinib is a small molecule inhibitor of certain receptor tyrosine kinases, and have improved outcomes for patients with advanced renal cell carcinoma. Inhibitory concentration of 50% cell growth of sorafenib significantly rose to 6.4-fold in a multidrug resistance protein 2 (MRP2) transfected cell line versus control cell line. The concentration of sorafenib was significantly decreased to 74% of control cells after 3 h treatment. In contrast, a tyrosine kinase inhibitor sunitinib did not show alteration of inhibitory concentration of 50% cell growth and accumulation into the cells of MRP2 transfected cells. The present study suggest that sorafenib is a substrate for MRP2, suggesting that MRP2 may implicate drug resistance to sorafenib.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B/metabolism , Antineoplastic Agents/metabolism , Benzenesulfonates/metabolism , Drug Resistance, Neoplasm , Indoles/metabolism , Protein Kinase Inhibitors/metabolism , Pyridines/metabolism , Pyrroles/metabolism , Animals , Antineoplastic Agents/pharmacology , Benzenesulfonates/pharmacology , Carcinoma, Renal Cell/metabolism , Cell Cycle/drug effects , Cell Line, Tumor , Cell Survival/drug effects , Humans , Indoles/pharmacology , Kidney Neoplasms/metabolism , Niacinamide/analogs & derivatives , Phenylurea Compounds , Protein Kinase Inhibitors/pharmacology , Protein-Tyrosine Kinases/antagonists & inhibitors , Pyridines/pharmacology , Pyrroles/pharmacology , Sorafenib , Substrate Specificity , Sunitinib , Swine , Transfection , ATP-Binding Cassette Sub-Family B Member 4
10.
Biol Pharm Bull ; 32(3): 493-6, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19252302

ABSTRACT

High-dose methotrexate (HDMTX) chemotherapy with leucovorin (LV) rescue has been used as a therapeutic strategy in oncology since the 1970s. Adverse reactions following extension of methotrexate (MTX) elimination are a crucial problem in HDMTX chemotherapy. MTX is a substrate for drug transporters, which are multidrug resistance protein 2 (Mrp2), organic anion transporter polypeptide 2 (Oatp2) and other transporters. We previously reported that MTX treatment downregulated the expression level of Mrp2 in rats. Here we examined the effect of MTX treatment on the expression of Oatp2, P-glycoprotein (P-gp) and bile salt export pump (Bsep) in rats. MTX was single-injected intraperitoneally at a dose of 150 mg/kg, and Western blot analysis was performed. The levels of Oatp2, P-gp and Bsep in the liver on day 4 after treatment were downregulated to 36.3 +/- 6.9%, 51.5 +/- 5.2% and 61.8 +/- 5.5% (mean +/- S.E.M.) of controls, respectively. Expression levels of P-gp in the kidney and ileum were also downregulated to 38.5 +/- 1.6% and 16.2 +/- 1.6% of controls, respectively. These effects of MTX were partially recovered by LV, which rescues normal cells from MTX toxicity. In conclusion, the result indicates that MTX treatment downregulates expression levels of Oatp2, P-gp and Bsep.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/biosynthesis , ATP-Binding Cassette Transporters/biosynthesis , Antimetabolites, Antineoplastic/toxicity , Folic Acid Antagonists/pharmacology , Methotrexate/toxicity , Organic Anion Transporters/biosynthesis , ATP Binding Cassette Transporter, Subfamily B, Member 11 , Animals , Male , Rats , Rats, Wistar
11.
Exp Cell Res ; 314(16): 3017-26, 2008 Oct 01.
Article in English | MEDLINE | ID: mdl-18671966

ABSTRACT

The major vault protein (MVP) is the major constituent of the vault particle, the largest ribonuclear protein complex described to date and is identical to lung resistance-related protein (LRP). Although MVP is also expressed in several normal tissues, little is known about its physiological role. MVP played a protective role against some xenobiotics and other stresses. We thus investigated the effect of osmotic stress on MVP expression by treating human colon cancer SW620 cells with sucrose or NaCl. The expression level of both MVP protein and MVP mRNA was increased by the osmostress. Sucrose or sodium chloride could also enhance MVP promoter activity. Inhibition of p38 MAPK in SW620 cells by SB203580 inhibited the expression of MVP under hyperosmotic stress. These findings suggested that osmotic stress up-regulated the MVP expression through p38 MAPK pathway. Down-regulation of MVP expression by MVP interfering RNA (RNAi) in SW620 cells increased the sensitivity of the cells to hyperosmotic stress and enhanced apoptosis. Furthermore, MVP RNAi prevented the osmotic stress-induced, time-dependent increase in phosphorylated Akt. These findings suggest that the PI3K/Akt pathway might be implicated in the cytoprotective effect of MVP. Our data demonstrate that exposure of cells to hyperosmotic stress induces MVP that might play an important role in the protection of the cells from the adverse effects of osmotic stress.


Subject(s)
Cell Line, Tumor , Colonic Neoplasms/metabolism , Gene Expression Regulation , Vault Ribonucleoprotein Particles/metabolism , Animals , Cell Survival , Chromones/metabolism , Enzyme Inhibitors/metabolism , Genes, Reporter , Humans , Morpholines/metabolism , Osmotic Pressure , Promoter Regions, Genetic , RNA Interference , RNA, Messenger/genetics , RNA, Messenger/metabolism , RNA, Small Interfering/genetics , RNA, Small Interfering/metabolism , Sodium Chloride/metabolism , Sucrose/metabolism , Vault Ribonucleoprotein Particles/genetics , p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors , p38 Mitogen-Activated Protein Kinases/metabolism
12.
Biochem Biophys Res Commun ; 370(2): 220-4, 2008 May 30.
Article in English | MEDLINE | ID: mdl-18359286

ABSTRACT

An angiogenic factor, thymidine phosphorylase (TP), confers resistance to apoptosis induced by hypoxia. We investigated the molecular basis for the suppressive effect of TP on hypoxia-induced apoptosis using Jurkat cells transfected with TP cDNA, Jurkat/TP, and a mock transfectant, Jurkat/CV. TP and 2-deoxy-d-ribose, a degradation product of thymidine generated by TP enzymatic activity, suppressed hypoxia-induced apoptosis. They also inhibited the upregulation of hypoxia-inducible factor (HIF) 1alpha and the proapoptotic factor, BNIP3, and caspase 3 activation induced by hypoxia. Introduction of siRNA against BNIP3 in Jurkat cells decreased the proportion of apoptotic cells under hypoxic condition. These findings suggest that the suppression of BNIP3 expression by TP prevents, at least in part, hypoxia-induced apoptosis. Expression levels of TP are elevated in many malignant solid tumors and thus 2-deoxy-d-ribose generated by TP in these tumors might play an important role in tumor progression by preventing hypoxia-induced apoptosis.


Subject(s)
Apoptosis , Membrane Proteins/antagonists & inhibitors , Proto-Oncogene Proteins/antagonists & inhibitors , Thymidine Phosphorylase/metabolism , Apoptosis/drug effects , Apoptosis/genetics , Caspase 3/metabolism , Caspase 8/metabolism , Cell Hypoxia/genetics , Deoxyribose/metabolism , Humans , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Jurkat Cells , Membrane Proteins/genetics , Proto-Oncogene Proteins/genetics , RNA, Small Interfering/genetics , RNA, Small Interfering/pharmacology , Thymidine Phosphorylase/genetics , Transfection
13.
Life Sci ; 81(2): 103-8, 2007 Jun 20.
Article in English | MEDLINE | ID: mdl-17543347

ABSTRACT

An herbal health care supplement, St John's Wort (SJW, Hypericum perforatum) has become widely used in the treatment of depression, and is known to interact with therapeutic drugs. Here we report a preventive effect of SJW on cisplatin nephrotoxicity in rats. Rats were given SJW (400 mg/kg/day, p.o.) for 10 consecutive days, and were injected with cisplatin (5 mg/kg, i.v.) on the day after the final SJW treatment. Cisplatin treatment increased the serum creatinine level, which is an index of nephrotoxicity, to 1.51+/-0.22 mg/dl (mean+/-SE) from 0.28+/-0.05 mg/dl (control) on day 5 after the cisplatin injection. This increase fell significantly to 0.86+/-0.13 mg/dl by pre-treatment with SJW. Cisplatin-induced histological abnormality of the kidney was blocked by pre-treatment with SJW. When SJW was administered for 10 days, the amounts of renal metallothionein (MT) and hepatic multidrug resistance protein 2 (Mrp2) were increased to 164.8+/-13.0% and 220.8+/-39.3% (mean+/-SE) of controls, respectively. GSH levels in the kidney and liver were not changed. Total and free cisplatin concentration in serum was not influenced by SJW treatment. In conclusion, the results suggest that pre-treatment with SJW may diminish cisplatin nephrotoxicity.


Subject(s)
Antineoplastic Agents/antagonists & inhibitors , Antineoplastic Agents/toxicity , Cisplatin/antagonists & inhibitors , Cisplatin/toxicity , Hypericum , Kidney Diseases/chemically induced , ATP-Binding Cassette Transporters/metabolism , Animals , Antineoplastic Agents/pharmacokinetics , Body Weight/drug effects , Cell Membrane/drug effects , Cell Membrane/metabolism , Cisplatin/pharmacokinetics , Creatinine/blood , Drug Interactions , Glutathione/metabolism , Kidney/drug effects , Kidney/metabolism , Kidney Diseases/metabolism , Male , Metallothionein/metabolism , Rats , Rats, Wistar
14.
Biol Pharm Bull ; 29(9): 1815-9, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16946491

ABSTRACT

Myoblasts respond to growth factor deprivation either by diffentiation into multinucleated myotubes or by undergoing apoptosis. The induction of apoptosis and differentiation in myogenic lineage may use overlapping cellular mechanisms. Here we demonstrate that the expression of the small heat shock protein alphaB-crystallin as well as MyoD and myogenin is induced during myogenic differentiation in C2C12 cells, and these inductions occur at an early stage in the differentiation in vitro. To investigate the effect of alphaB-crystallin on myogenic differentiation and apoptosis, C2C12 cells were infected with adenovirus vector bearing full-length alphaB-crystallin cDNA. Overexpression of alphaB-crystallin in C2C12 cells suppressed differentiation-induced apoptosis and activation of caspase 3, and also decreased the expression of MyoD and myogenin during myogenic differentiation of C2C12 cells induced by the differentiation medium. Our findings suggest that stress such as growth factor deprivation plays an important role in triggering apoptosis associated with myogenic differentiation and alphaB-crystallin suppressed the differentiation, apoptosis and caspase 3 activity.


Subject(s)
Caspases/physiology , Muscle Development , alpha-Crystallin B Chain/physiology , Animals , Apoptosis , Caspase 3 , Cell Differentiation , Cells, Cultured , Enzyme Activation , Mice , Muscle, Skeletal/cytology
15.
Cancer Sci ; 97(11): 1260-6, 2006 Nov.
Article in English | MEDLINE | ID: mdl-16925582

ABSTRACT

The ATP binding cassette (ABC) transporters, multidrug resistance protein 2 (Mrp2; Abcc2) and breast cancer resistance protein (Bcrp; Abcg2), and organic anion transporters (Oats) mediate excretion of methotrexate (MTX) and many other drugs. However, it is not known whether MTX treatment leads to any changes in the expression of these transporters. We examined the effect of MTX treatment on expression of Mrp2, Bcrp and Oats in rats. MTX was single injected intraperitoneally at doses of 10, 50 and 150 mg/kg, and then Western blot analysis was performed. The levels of Mrp2, Oat1 and Oat2 on day 1 after the treatment showed no significant change. Four days after injection of 150 mg/kg MTX, the Mrp2 levels in the liver and ileum, but not in the kidney, were markedly down-regulated to 20 +/- 3.6% and 8.9 +/- 3.8% (mean +/- SEM) of controls, respectively. Renal Oat1 and Oat3 were also down-regulated to 56.4 +/- 4.3% (Oat1) and 54.3 +/- 5.5% (Oat3) of controls. These effects of MTX were almost recovered by leucovorin which rescues normal cells from MTX toxicity. MTX treatment also decreased mRNA levels of constitutive androstane receptor (CAR) and pregnane X receptor (PXR) to 65.5 +/- 17.9% and 59.6 +/- 14.5% of controls in the liver, respectively. MTX treatment has no apparent effect on expression levels of Bcrp, cytochrome P450 2B6 and 3A1. In conclusion, these data indicate that MTX treatment down-regulates expression levels of Mrp2, Oat1 and Oat3, and its effects are recovered by leucovorin.


Subject(s)
ATP-Binding Cassette Transporters/blood , Antimetabolites, Antineoplastic/pharmacology , Methotrexate/pharmacology , Organic Anion Transport Protein 1/blood , Organic Anion Transporters, Sodium-Independent/blood , ATP Binding Cassette Transporter, Subfamily G, Member 2 , ATP-Binding Cassette Transporters/genetics , Animals , Blotting, Western , Down-Regulation , Heart/drug effects , Heart/physiology , Leucovorin/pharmacology , Male , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats , Rats, Wistar , Reverse Transcriptase Polymerase Chain Reaction , Vitamin B Complex/pharmacology
16.
Biochem Biophys Res Commun ; 342(1): 280-5, 2006 Mar 31.
Article in English | MEDLINE | ID: mdl-16480951

ABSTRACT

An angiogenic factor, platelet-derived endothelial cell growth factor/thymidine phosphorylase (TP), stimulates the chemotaxis of endothelial cells and confers resistance to apoptosis induced by hypoxia. 2-Deoxy-d-ribose, a degradation product of thymidine generated by TP enzymatic activity, partially prevented hypoxia-induced apoptosis. 2-Deoxy-d-ribose inhibited hypoxia-induced phosphorylation of p38 mitogen-activated protein kinase (MAPK) but not c-jun NH(2)-terminal kinase/stress-activated protein kinase in human leukemia HL-60 cells. 2-Deoxy-d-ribose also suppressed the levels of Bax attached to mitochondria under hypoxic conditions. SB203580, a specific inhibitor of the p38 MAPK, suppressed the hypoxia-induced apoptosis of HL-60 cells. These findings suggest that one of the molecular bases for resistance to hypoxia-induced apoptosis conferred by 2-deoxy-d-ribose is the inhibition of the p38 signaling pathway. The expression levels of TP are elevated in many malignant solid tumors and thus the 2-deoxy-d-ribose generated by TP in these tumors may play an important role in tumor progression by preventing hypoxia-induced apoptosis.


Subject(s)
Apoptosis/drug effects , Cell Hypoxia , Deoxyribose/pharmacology , p38 Mitogen-Activated Protein Kinases/metabolism , Cell Line, Tumor , Cell Polarity/drug effects , Cell Shape , Extracellular Signal-Regulated MAP Kinases/metabolism , Humans , Imidazoles/pharmacology , JNK Mitogen-Activated Protein Kinases/metabolism , Mitochondria/drug effects , Phosphorylation/drug effects , Protein Transport , Pyridines/pharmacology , bcl-2-Associated X Protein/metabolism
17.
Cancer Sci ; 96(6): 372-6, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15958061

ABSTRACT

A major impediment to cancer treatment is the development of resistance by the tumor. P-glycoprotein (P-gp) and multidrug resistance protein 1 (MRP1) are involved in multidrug resistance. In addition to the extrusion of chemotherapeutic agents through these transporters, it has been reported that there are differences in the intracellular distribution of chemotherapeutic agents between drug resistant cells and sensitive cells. Cepharanthine is a plant alkaloid that effectively reverses resistance to anticancer agents. It has been previously shown that cepharanthine is an effective agent for the reversal of resistance in P-gp-overexpressing cells. Cepharanthine has also been reported to have numerous pharmacological effects besides the inhibition of P-gp. It has also been found that cepharanthine enhanced sensitivity to doxorubicin (ADM) and vincristine (VCR), and enhanced apoptosis induced by ADM and VCR of P-gp negative K562 cells. Cepharanthine changed the distribution of ADM from cytoplasmic vesicles to nucleoplasm in K562 cells by inhibiting the acidification of cytoplasmic organelles. Cepharanthine in combination with ADM should be useful for treating patients with tumors.


Subject(s)
Alkaloids/pharmacology , Antineoplastic Agents, Phytogenic/pharmacology , Drug Resistance, Multiple , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology , Pancreatic Neoplasms/pathology , ATP Binding Cassette Transporter, Subfamily B, Member 1/biosynthesis , ATP Binding Cassette Transporter, Subfamily B, Member 1/physiology , Antibiotics, Antineoplastic/pharmacology , Apoptosis , Benzylisoquinolines , Doxorubicin/pharmacology , Drug Interactions , Humans , Tumor Cells, Cultured , Vincristine/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...